Myelin and Multiple Sclerosis

Myelin is the insulation that coats the nerve cells in the brain and spinal cord. Multiple sclerosis damages myelin, causing a range of symptoms from paralysis to cognitive disorders. Finding a way to repair damaged myelin has the potential to stop MS in its tracks.

The Myelin Repair Foundation is the largest research organization focused exclusively on developing myelin repair treatments for those living with MS.

Recently diagnosed with MS? Find out about our promising research and five years of progress.

Find out more:

• Myelin repair as a treatment option.
• Why our research is accelerating discovery.
• Read our Where are the cures? brochure to learn more about the challenges facing medical research and drug development
• Read our Promises Made, Promises Kept (PDF) on our progress from 2004-2009 and our goals for the next 5 years.
• A Summary of Scientific Findings 2004-09 (PDF)

Proven Methods, Stunning Results

The Myelin Repair Foundation Accelerated Research Collaboration™ (ARC™) model is a radical new research process designed to speed academic discoveries into commercially viable therapeutic targets and patient treatments.

To date, we are the only organization involved in the entire process of bringing patient treatments to market.

President’s Update (2/2010): This month the Myelin Repair Foundation is launching a new web site called Where are the Cures? As our friends and supporters know, the mission of the MRF has always been twofold: first to bring a myelin repair treatment to market as quickly as possible and second to demonstrate the ARC model and prove that medical research and drug development for all diseases can be accelerated.

Read more...

Latest News:The MRF calls for accountability in medical research, asks "Where Are The Cures?" (PDF)

"The MRF is actively working at changing the way we as drug discoverers think and operate, and we are encouraging others to do likewise. We are not just being angry and pointing fingers at the broken biomedical research process. We are doing something about it."

--MIKE GRESSER, MRF Chief Scientific Officer and former Amgen VP of Research on Inflammation